Crescent Biopharma (C68) Price & Analysis

2 Followers

C68 Stock Chart & Stats

€15.70

Market closed

€15.70

Day’s Range― - ―

52-Week Range€6.70 - €22.80

Previous CloseN/A

VolumeN/A

Average Volume (3M)22.00

Market Cap

€404.71M

Enterprise Value€314.46M

Total Cash (Recent Filing)€189.16M

Total Debt (Recent Filing)€1.54M

Price to Earnings (P/E)―

Beta0.65

Next Earnings

Jul 30, 2026

EPS Estimate

-0.67

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-10.91

Shares Outstanding27,571,936

10 Day Avg. Volume21

30 Day Avg. Volume22

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)0.61

Price to Sales (P/S)11.39

P/FCF Ratio-1.70

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€27.18

Price Target Upside73.12% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

EPS Forecast (FY)-2.73

Revenue Forecast (FY)€1.65M

Bulls Say, Bears Say

Bulls Say

Revenue & Gross MarginSharp TTM revenue growth combined with an exceptionally high gross margin (~96%) implies strong unit economics and improving commercialization. Durable because high margin on recorded sales can scale profitably as revenues grow, supporting long-term margin sustainability if operating leverage improves.

Low Leverage / Balance SheetVery low debt and a sizable equity base provide substantial financial flexibility, lowering bankruptcy and interest-rate risks. This durable strength supports funding operating needs, strategic investment or partnerships without immediate refinancing pressure, improving resilience over months.

Improving Cash BurnMeaningful reduction in operating cash outflows versus prior year shows execution progress and a narrowing funding gap. A sustained improvement in cash burn is a structural positive: it lowers external financing reliance and extends runway, making the business model less dependent on near-term capital raises.

Bears Say

Deep Ongoing LossesExtremely negative net margins reflect operating costs far exceeding revenue, a structural profitability gap. Persistent deep losses can erode capital, force strategic trade-offs, and require ongoing financing; without sustained margin improvement, long-term viability and investor returns remain at risk.

Negative Free Cash FlowContinued negative free cash flow indicates the company consumes cash to operate and grow. This creates a structural funding requirement that raises dilution or debt risk, constraining R&D and commercial investments and increasing vulnerability if capital markets tighten or financing costs rise.

Persistently Negative ROEA deeply negative ROE shows the company is not generating returns on shareholder capital and risks eroding equity value over time. Even with a strong equity base, sustained negative returns signal inefficient capital allocation and question long-term shareholder value creation.

Crescent Biopharma News

BTIG says others may be interested in Apogee Therapeutics

BTIG analyst Julian Harrison says AbbVie (ABBV) can leverage its existing dermatology channels and compete in atopic dermatitis...

19d ago

JNJ

NVS

Campbell, Crescent, Cardiff, Sherwin, Take-Two Trending With Analysts

Analysts are intrested in these 5 stocks: ( ($CPB) ), ( ($CBIO) ), ( ($CRDF) ), ( ($SHW)...

1M ago

CPB

SHW

Crescent Biopharma shareholders back directors, pay and auditor

Crescent Biopharma ( ($CBIO) ) just unveiled an update. On June 2, 2026, Crescent Biopharma, Inc. held its...

1M ago

CBIO

Crescent Biopharma downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright downgraded Crescent Biopharma (CBIO) to Neutral from Buy without a price target saying the ivonescimab copycat...

1M ago

CBIO

Crescent Biopharma reports Q1 EPS (70c), consensus (79c)

Reports Q1 revenue $1.04M, consensus $357,140. “Crescent’s execution on the advancement of our pipeline this quarter positions us...

2M ago

CBIO

Crescent Biopharma management to meet with Cantor Fitzgerald

Meeting to be held in San Francisco on April 14, in Denver on April 15 and in New...

3M ago

CBIO

Crescent Biopharma price target lowered to $22 from $25 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Crescent Biopharma (CBIO) to $22 from $25 and keeps a...

4M ago

CBIO

Crescent Biopharma reports Q4 EPS ($4.01) vs. ($19.74) last year

Reports Q4 revenue $10.8M vs .$0 last year. “2025 was a transformational year for Crescent and our efforts...

5M ago

CBIO

Crescent Biopharma sees cash runway into 2028

Cash and cash equivalents were $213.2 million as of December 31, 2025, which is anticipated to fund operations...

5M ago

CBIO

3 ‘Strong Buy’ Stocks to Buy Now, 2/19/2026, According to Top Analysts

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below...

5M ago

CBIO

CHWY

Crescent Biopharma announces grants of inducement awards

Crescent Biopharma (CBIO) announced that the independent Compensation Committee of its Board of Directors approved the grant of...

5M ago

CBIO

Crescent Biopharma: Fast-Follower Potential of CR-001 and Strategic Partnerships Support Buy Rating and $25 Target

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Crescent Biopharma today and set a price target...

5M ago

CBIO

Crescent Biopharma announces first patient dosed in ASCENT Phase 1/2 trial

Crescent Biopharma (CBIO) announced that the first patient has been dosed in its global ASCEND Phase 1/2 clinical...

5M ago

CBIO

Crescent Biopharma initiated with an Overweight at Piper Sandler

Piper Sandler initiated coverage of Crescent Biopharma (CBIO) with an Overweight rating and $35 price target The firm...

5M ago

CBIO

C68 FAQ

What was Crescent Biopharma’s price range in the past 12 months?

Crescent Biopharma lowest stock price was €6.70 and its highest was €22.80 in the past 12 months.

What is Crescent Biopharma’s market cap?

Crescent Biopharma’s market cap is €404.71M.

When is Crescent Biopharma’s upcoming earnings report date?

Crescent Biopharma’s upcoming earnings report date is Jul 30, 2026 which is in 19 days.

How were Crescent Biopharma’s earnings last quarter?

Crescent Biopharma released its earnings results on Apr 29, 2026. The company reported -€0.599 earnings per share for the quarter, beating the consensus estimate of -€0.752 by €0.153.

Is Crescent Biopharma overvalued?

According to Wall Street analysts Crescent Biopharma’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Crescent Biopharma pay dividends?

Crescent Biopharma does not currently pay dividends.

What is Crescent Biopharma’s EPS estimate?

Crescent Biopharma’s EPS estimate is -0.67.

How many shares outstanding does Crescent Biopharma have?

Crescent Biopharma has 27,571,936 shares outstanding.

What happened to Crescent Biopharma’s price movement after its last earnings report?

Crescent Biopharma reported an EPS of -€0.599 in its last earnings report, beating expectations of -€0.752. Following the earnings report the stock price went down -18.571%.

Which hedge fund is a major shareholder of Crescent Biopharma?

Currently, no hedge funds are holding shares in DE:C68

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Crescent Biopharma Stock Smart Score

Underperform

Analyst Consensus

Strong Buy

Average Price Target:
€27.18 (73.12% Upside)

Technicals

Fundamentals

Return on Equity

-100.86%

Trailing 12-Months

Asset Growth

3223.16%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Crescent Biopharma

Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes CR-001, a proprietary bispecific antibody engineered to simultaneously target PD-1 and VEGF pathways for the treatment of solid tumors. The company's pipeline further comprises CR-002 and CR-003. Crescent Biopharma also maintains a strategic alliance with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., focusing on the joint advancement and commercialization of oncology therapeutics, encompassing innovative combination approaches. The company's operations are headquartered in Waltham, Massachusetts.

Crescent Biopharma (C68) Earnings & Revenues

Historic Earnings Reports

C68 Stock 12 Month Forecast

Average Price Target

€27.18

▲(73.12% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"€7","13":"€13","19":"€19","25":"€25","31":"€31"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30.68659965,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€30.69</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":27.17955969,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€27.18</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23.67251973,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€23.67</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,13,19,25,31],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.9,16.114353819230768,17.328707638461537,18.543061457692307,19.757415276923076,20.971769096153846,22.186122915384615,23.400476734615385,24.614830553846154,25.829184373076924,27.043538192307693,28.257892011538463,29.472245830769232,{"y":30.68659965,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.9,15.844581514615385,16.78916302923077,17.733744543846154,18.67832605846154,19.622907573076922,20.56748908769231,21.512070602307695,22.456652116923078,23.40123363153846,24.345815146153846,25.290396660769233,26.23497817538462,{"y":27.17955969,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.9,15.57480921,16.24961842,16.92442763,17.59923684,18.274046050000003,18.948855260000002,19.62366447,20.29847368,20.97328289,21.6480921,22.32290131,22.99771052,{"y":23.67251973,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.174,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.174,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.174,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.174,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.1,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.1,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.5,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.9,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.55,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.1,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.7,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.9,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >